Ecabet sodium: Preliminary Phase IIb data

ISTA reported preliminary results from a double-blind, placebo-controlled, U.S. Phase IIb trial in 162 patients that showed 3% ecabet (lower dose) led to a positive trend toward reducing symptoms of d...